TY - JOUR
T1 - Branched chain amino acids are associated with metabolic complications in liver transplant recipients
AU - Böhler, Marco
AU - van den Berg, Eline H.
AU - TransplantLines Investigators
AU - Almanza, Maria C.T.
AU - Connelly, Margery A.
AU - Bakker, Stephan J.L.
AU - de Meijer, Vincent E.
AU - Dullaart, Robin P.F.
AU - Blokzijl, Hans
AU - Hak, E.
AU - Hepkema, B. G.
AU - Klont, F.
AU - Knobbe, T. J.
AU - Kremer, D.
AU - Leuvenink, H. G.D.
AU - Lexmond, W. S.
AU - Niesters, H. G.M.
AU - van Pelt, L. J.
AU - Pol, R. A.
AU - Porte, R. J.
AU - Ranchor, A. V.
AU - Sanders, J. S.F.
AU - Siebelink, M. J.
AU - Slart, R. J.H.J.A.
AU - Swarte, J. C.
AU - Touw, D. J.
AU - van den Heuvel, M. C.
AU - van Leer-Buter, C.
AU - van Londen, M.
AU - Verschuuren, E. A.M.
AU - Vos, M. J.
AU - Weersma, R. K.
N1 - Publisher Copyright:
© 2022 The Author(s)
PY - 2022/4
Y1 - 2022/4
N2 - Background: Obesity, dyslipidemia and type 2 diabetes (T2D) contribute substantially to increased cardiovascular morbidity and mortality in patients after orthotopic liver transplantation (OLTx). Elevated plasma branched chain amino acids (BCAA) are linked to metabolic disturbances and cardiovascular disease (CVD) risk profiles in several non-OLTx populations. Methods: Cross-sectional analysis of liver transplant recipients from TransplantLines, a single-center biobank and cohort study. BCAA plasma levels were measured by means of nuclear-magnetic resonance spectroscopy. CVD and cardiometabolic factors were collected by using data from electronic patient records. Associations were determined between BCAA plasma levels and T2D, Metabolic Syndrome (MetS), CVD as well as mTOR inhibition in liver transplant recipients. Results: 336 Patients were divided into sex-stratified tertiles of total BCAA. MetS (P < 0.001) and T2D (P = 0.002) were significantly more frequent in subjects in the highest BCAA tertile. In logistic regression analyses, the multivariable adjusted odds ratio (OR) per 1 standard deviation increase in BCAA was 1.68 (95%CI: 1.18–2.20, P = 0.003) for MetS and 1.60 (95%CI: 1.14–2.23, P = 0.006) for T2D. Use of Sirolimus (mTOR inhibitor) was significantly associated with higher BCAA plasma levels, independent of age, sex, time after OLTx, MetS and other immunosuppressive medication (adjusted P = 0.002). Conclusion: Elevated BCAA plasma levels are associated with T2D, MetS and use of Sirolimus in liver transplant recipients. BCAA plasma levels may represent a valuable biomarker for cardiometabolic complications after OLTx.
AB - Background: Obesity, dyslipidemia and type 2 diabetes (T2D) contribute substantially to increased cardiovascular morbidity and mortality in patients after orthotopic liver transplantation (OLTx). Elevated plasma branched chain amino acids (BCAA) are linked to metabolic disturbances and cardiovascular disease (CVD) risk profiles in several non-OLTx populations. Methods: Cross-sectional analysis of liver transplant recipients from TransplantLines, a single-center biobank and cohort study. BCAA plasma levels were measured by means of nuclear-magnetic resonance spectroscopy. CVD and cardiometabolic factors were collected by using data from electronic patient records. Associations were determined between BCAA plasma levels and T2D, Metabolic Syndrome (MetS), CVD as well as mTOR inhibition in liver transplant recipients. Results: 336 Patients were divided into sex-stratified tertiles of total BCAA. MetS (P < 0.001) and T2D (P = 0.002) were significantly more frequent in subjects in the highest BCAA tertile. In logistic regression analyses, the multivariable adjusted odds ratio (OR) per 1 standard deviation increase in BCAA was 1.68 (95%CI: 1.18–2.20, P = 0.003) for MetS and 1.60 (95%CI: 1.14–2.23, P = 0.006) for T2D. Use of Sirolimus (mTOR inhibitor) was significantly associated with higher BCAA plasma levels, independent of age, sex, time after OLTx, MetS and other immunosuppressive medication (adjusted P = 0.002). Conclusion: Elevated BCAA plasma levels are associated with T2D, MetS and use of Sirolimus in liver transplant recipients. BCAA plasma levels may represent a valuable biomarker for cardiometabolic complications after OLTx.
UR - http://www.scopus.com/inward/record.url?scp=85125675726&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2022.01.009
DO - 10.1016/j.clinbiochem.2022.01.009
M3 - Article
C2 - 35143831
AN - SCOPUS:85125675726
SN - 0009-9120
VL - 102
SP - 26
EP - 33
JO - Clinical Biochemistry
JF - Clinical Biochemistry
ER -
